[{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SNIPR Biome \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"SNIPR Biome \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Cytoreason","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Cytoreason","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytoreason \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Cytoreason \/ Sanofi"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Heptares \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Heptares \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Group Corporation \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Group Corporation \/ Inapplicable"},{"orgOrder":0,"company":"PharmaBiome","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"PharmaBiome","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaBiome \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"PharmaBiome \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Cowellnex","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Siolta Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Siolta Therapeutics \/ Cowellnex","highestDevelopmentStatusID":"2","companyTruncated":"Siolta Therapeutics \/ Cowellnex"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Celsius Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Celsius Therapeutics \/ University of Oxford","highestDevelopmentStatusID":"2","companyTruncated":"Celsius Therapeutics \/ University of Oxford"},{"orgOrder":0,"company":"Scipher Medicine","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Scipher Medicine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scipher Medicine \/ Galapagos","highestDevelopmentStatusID":"2","companyTruncated":"Scipher Medicine \/ Galapagos"},{"orgOrder":0,"company":"Second Genome","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Second Genome","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Second Genome \/ Gilead Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Second Genome \/ Gilead Sciences"},{"orgOrder":0,"company":"Kallyope","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Kallyope","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kallyope \/ Sosei Group Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Kallyope \/ Sosei Group Corporation"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Sonoma Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sonoma Biotherapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Sonoma Biotherapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Codexis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Collaboration","leadProduct":"CDX-7108","moa":"Pancreatic enzyme","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Codexis","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codexis \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"2","companyTruncated":"Codexis \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Sinopia Biosciences","sponsor":"NIDCR","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Sinopia Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinopia Biosciences \/ NIDCR","highestDevelopmentStatusID":"2","companyTruncated":"Sinopia Biosciences \/ NIDCR"},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Novome Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novome Biotechnologies \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"Novome Biotechnologies \/ Genentech"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : Under the agreement, Siolta will develop live biotherapeutic products with joint research program with Cowellnex for treating necrotizing enterocolitis in infants.

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Undisclosed

                          January 29, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Discovery

                          Sponsor : Cowellnex

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : The funding aims to support the company in discovering novel small molecules and identifying promising treatment candidates for oral mucositis.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          December 09, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Discovery

                          Sponsor : NIDCR

                          Deal Size : $2.2 million

                          Deal Type : Funding

                          blank

                          03

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : The funding from the Bill & Melinda Gates Foundation will be used to develop a microbiome-directed intervention designed to improve EED by reducing gut entero-pathogen burden in pregnant women.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          June 28, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Discovery

                          Sponsor : Bill & Melinda Gates Foundation

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          04

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : The collaboration will bring together Regeneron’s VelociSuite technologies to discover, develop and commercialize engineered Treg therapies for autoimmune diseases.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : $75.0 million

                          April 09, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Discovery

                          Sponsor : Regeneron Pharmaceuticals

                          Deal Size : $120.0 million

                          Deal Type : Collaboration

                          blank

                          05

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : Under the collaboration, Ferring will get exclusive rights to develop, manufacture and commercialise next generation microbiome-based therapeutics within the field of gastroenterology arising out of the collaboration.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 12, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Discovery

                          Sponsor : Ferring Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          06

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : The company successful identification, validation and nomination of a first G protein-coupled receptor (GPCR) target to enter a therapeutic discovery program for gastrointestinal diseases.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 11, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Discovery

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : Verily’s proprietary Immune Profiler is a next generation immune mapping platform that will be used to identify GPCR targets that represent new opportunities to modulate immune cell function and ameliorate disease pathology.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 10, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Discovery

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : The collaboration will support Sanofi’s use of CytoReason’s computational disease models to develop new targets for inflammatory bowel disease (IBD), to identify patient subtypes and pair them with IBD targets.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          January 23, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Discovery

                          Sponsor : Sanofi

                          Deal Size : Undisclosed

                          Deal Type : Expanded Collaboration

                          blank

                          09

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : The focus of the agreements is to apply the innovative technologies and research capabilities of the respective academic groups to identify, validate and prioritize key GPCRs driving gastrointestinal and immune disorders, including IBD, as targets for SB...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          August 12, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Discovery

                          Sponsor : University of Oxford

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          10

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : The agreement will leverage Sosei Heptares’ GPCR Diversified Compound Library and GPCR expertise with the innovative Kallyope gut-brain axis platform, which combines single-cell sequencing, circuit mapping, computational biology and enteroid phenotypic...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 17, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Discovery

                          Sponsor : Sosei Group Corporation

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank